Laura Sepp-Lorenzino, Ph.D. is a biotech executive with expertise in drug development, particularly in nucleic acid therapies. She currently serves on the board of directors of Taysha Gene Therapies, AskBio Biopharmaceutical, Sail Medicines, the Alliance for Regenerative Medicine, and the American Association of Cell and Gene Therapy. Additionally, she chairs the scientific advisory board of Travin Bio and is an SAB member for Thermo Fisher Scientific, MRC’s U.K. Nucleic Acid Therapy Accelerator, and Arsenal Capital Partners.

Previously, Laura was Chief Scientific Officer at Intellia Therapeutics (2019–2025), where she played a pivotal role in shaping the company’s strategic direction, fostering a robust and diversified CRISPR platform, and driving groundbreaking advances in in vivo genome editing. Under her leadership, Intellia demonstrated the first successful in vivo genome editing in humans and advanced two candidates into pivotal trials. Before Intellia, she served as VP, Head of Nucleic Acid Therapies at Vertex Pharmaceuticals, as well as VP and entrepreneur-in-residence at Alnylam Pharmaceuticals, and Executive Director of RNA Therapeutics at Merck & Co.

Laura’s expertise extends beyond nucleic acid therapies, encompassing oncology drug discovery and development, honed through leadership roles at Merck West Point and Memorial Sloan-Kettering Cancer Center. She holds a professional degree in Biochemistry from the University of Buenos Aires, Argentina, and earned her M.S. and Ph.D. in Biochemistry from New York University. She also contributes to the scientific community as an editorial board member of Nucleic Acid Therapeutics and Molecular Therapy Nucleic Acids.